Opko Health OPK Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Gross Profit by Business | |||||
| Diagnostics | $62.92M-19.9% | $78.56M+13.1% | $69.45M-45.8% | $128.08M— | |
| Pharmaceutical | $143.02M+2.2% | $139.95M-43.7% | $248.68M— | —— | |
| Operating Income by Business | |||||
| Pharmaceutical | -$98.34M-13.3% | -$86.79M— | —— | -$12.95M+32.0% | |
| Total Assets by Business | |||||
| Diagnostics | $1.68B-24.7% | $2.24B-14.2% | $2.61B-20.7% | $3.29B-34.6% | |
| Selling General And Administrative Expense by Business | |||||
| Diagnostics | $129.3M-37.0% | $205.19M+1.4% | $202.34M-28.9% | $284.39M— | |
| Pharmaceutical | $53.87M-7.1% | $58.01M+4.2% | $55.69M— | —— | |
| Research And Development Expense by Business | |||||
| Diagnostics | $1.64M-21.1% | $2.07M-17.3% | $2.51M-79.1% | $12.02M— | |
| Pharmaceutical | $121.91M+18.3% | $103.02M+18.4% | $87.01M— | —— | |
| D&A by Business | |||||
| Diagnostics | $19.37M-26.1% | $26.22M-22.3% | $33.75M-18.6% | $41.45M-20.7% | |
| Pharmaceutical | $72.26M+0.4% | $71.96M+1.0% | $71.25M+3.5% | $68.82M+160% | |
| Goodwill by Business | |||||
| Diagnostics | $653.77M-25.3% | $874.88M-22.7% | $1.13B0.0% | $1.13B-28.7% | |
| Cost of Goods Sold by Business | |||||
| Diagnostics | $307.35M-23.6% | $402.11M-9.8% | $445.83M-29.0% | $627.55M— | |
| Pharmaceutical | $93.59M+1.2% | $92.52M-7.0% | $99.54M— | —— | |
| Amortization Of Intangible Assets by Business | |||||
| Diagnostics | $12.3M-27.3% | $16.92M-16.2% | $20.2M-15.4% | $23.87M— | |
| Pharmaceutical | $65.59M-0.2% | $65.72M-0.2% | $65.84M— | —— | |
| Goodwill Foreign Currency Translation Gain Loss by Business | |||||
| Diagnostics | $0— | $0— | $0— | $0+100% | |
| Goodwill Impaired Accumulated Impairment Loss by Business | |||||
| Diagnostics | $71.91M0.0% | $71.91M— | —— | —— | |
| Revenue by Product | |||||
| Rayaldee | $59.39M-14.3% | $69.3M+2.6% | $67.55M+13.4% | $59.56M-7.4% | |
| Transfer Of Intellectual Property And Other | $79.7M+3.0% | $77.4M-57.2% | $180.73M+70.9% | $105.76M+469% | |
| Cost of Goods Sold by Product | |||||
| Product | $93.59M+1.2% | $92.52M-7.0% | $99.54M+12.6% | $88.43M-2.8% | |
| Service | $307.35M-23.6% | $402.11M-9.8% | $445.83M-29.0% | $627.55M-43.1% | |
| Revenue by Geography | |||||
| CL | $62.38M-4.1% | $65.05M-5.0% | $68.49M+10.4% | $62.04M-2.8% | |
| ES | $26.72M+8.5% | $24.63M+4.7% | $23.52M+4.6% | $22.48M-0.9% | |
| IE | $51.4M+6.2% | $48.4M-65.8% | $141.47M+20.7% | $117.22M+257% | |
| IL | $523K-70.5% | $1.77M-81.8% | $9.74M+153% | $3.85M+7.9% | |
| MX | $25.52M+6.9% | $23.87M+18.1% | $20.22M+39.0% | $14.55M+32.2% | |
| Other Countries | $4.27M+36.8% | $3.12M+39.1% | $2.25M+160% | $862K+70.0% | |
| US | $436.06M-20.2% | $546.3M-8.6% | $597.82M-23.7% | $783.21M-52.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Opko Health break its business down?
- Opko Health (OPK) reports gross profit by business across 2 parts — Diagnostics and Pharmaceutical. Each is extracted from the segment footnotes and tracked over time.
- Where does Opko Health's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Opko Health's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
